Compositions and methods for treating conditions of compromised skin barrier function

1. A method for treating eczema in a subject in need thereof, comprising:

applying to the skin of the subject a composition comprising

a) a reactive reinforcing component and

b) a cross-linking component;

wherein the reactive reinforcing component comprises a reactive constituent and a reinforcing constituent;

wherein the reactive constituent comprises at least one organopolysiloxane ingredient of formula II and at least one hydride functionalized polysiloxane ingredient of formula III;

 wherein

R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl;

p and q are each independently an integer from between 10 and 6000;

R 1b , R 2b , R 3b , R 6b , R 7b and R 8b are C 1-20 alkyl;

R 4b , R 5b , R 9b and R 10b are in each independently selected from hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl, wherein at least two of R 4b , R 5b , R 9b and R 10b are hydrogen; and

m and n are each independently an integer from between 10 and 6000;

wherein the organopolysiloxane ingredient comprises at least one high viscosity organopolysiloxane and at least one low viscosity organopolysiloxane,

wherein said high viscosity organopolysiloxane has a viscosity of about 100,000 to about 500,000 cSt or cP at 25° C. and the low viscosity organopolysiloxane has a viscosity of about 100 to about 50,000 cSt or cP at 25° C.;

wherein the high viscosity organopolysiloxane is vinyl terminated;

wherein the low viscosity organopolysiloxane is vinyl terminated; and

wherein said cross-linking component facilitates in situ cross-linking of the reactive reinforcing component, such that a film is formed on skin, thereby treating eczema in the subject.

2. The method of claim 1 , wherein the film is used in combination with one or more additional therapeutic agents.

3. The method of claim 1 , wherein the reactive reinforcing component has a viscosity of about 50,000 to about 700,000 cSt or cP at 25° C.

4. The method of claim 1 , wherein the reactive reinforcing component has a vinyl to functional hydride ratio of about 1:10 to about 1:100.

5. The method of claim 1 , wherein said high viscosity organopolvsiloxane has a viscosity of about 100,000 to about 175,000 cSt or cP at 25° C.

6. The method of claim 1 , wherein said low viscosity organopolvsiloxane has a viscosity of about 3,500 to about 20,000 cSt or cP at 25° C.

7. The method of claim 1 , wherein the crosslinking component comprises a metal catalyst.

8. The method of claim 1 , wherein the film is on the skin for at least 1 hour.

9. The method of claim 1 , wherein the film is on the skin for at least 4 hours.

10. The method of claim 1 , wherein the film is on the skin for at least 10 hours.

11. The method of claim 1 , wherein the film is on the skin for at least 16 hours.

12. The method of claim 1 , wherein the film is on the skin for at least 24 hours.

13. The method of claim 1 , wherein the ratio of the viscosity of the high viscosity organopolysiloxane to the viscosity of the low viscosity organopolysiloxane is between 100 and 1.

14. The method of claim 1 , wherein the fractional weight of the high viscosity organopolysiloxane to the viscosity of the low viscosity organopolysiloxane is between 0.1 and 0.5.

15. A method for treating eczema in a subject in need thereof, comprising:

applying to the skin of the subject a composition comprising

a) a reactive reinforcing component

wherein the reactive reinforcing component comprises a reactive constituent and a reinforcing constituent;

wherein the reactive constituent comprises at least one organopolysiloxane ingredient of formula II and at least one hydride functionalized polysiloxane ingredient of formula III;

 wherein

R 1a′ , R 3a′ , R 4a′ , R 5a′ , R 6a′ , R 8a′ , R 9a′ and R 10a′ are in each occurrence independently C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl;

p and q are each independently an integer from between 10 and 6000;

R 1b , R 2b , R 3b , R 6b , R 7b and R 8b are C 1-20 alkyl;

R 4b , R 5b , R 9b and R 10b are in each independently selected from hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl or C 1-20 alkoxyl, wherein at least two of R 4b , R 5b , R 9b and R 10b are hydrogen; and

m and n are each independently an integer from between 10 and 6000;

wherein the organopolysiloxane ingredient comprises at least one high viscosity organopolysiloxane and at least one low viscosity organopolysiloxane;

wherein said high viscosity organopolysiloxane has a viscosity of about 100,000 to about 175,000 cSt or cP at 25° C. and the low viscosity organopolysiloxane has a viscosity of about 3,500 to about 20,000 cSt or cP at 25° C.;

wherein the high viscosity organopolysiloxane is vinyl terminated;

wherein the low viscosity organopolysiloxane is vinyl terminated; and

wherein said reactive reinforcing component has a viscosity of about 50,000 to about 700,000 cSt or cP at 25° C.; and

b) a cross-linking component;

wherein said cross-linking component facilitates in situ cross-linking of the reactive reinforcing component, such that a film is formed on skin, thereby treating eczema in the subject.

16. The method of claim 15 , wherein said high viscosity organopolysiloxane comprises vinyl terminated polydimethylsiloxane and the low viscosity organopolysiloxane comprises vinyl terminated polydimethylsiloxane.

17. The method of claim 15 , wherein the high viscosity organopolysiloxane has a weight percent of vinyl of about 0.01 to about 0.1 or a vinyl equivalent per kilogram of about 0.01 to about 0.02 or a combination of both and the low viscosity organopolysiloxane has a weight percent of vinyl of about 0.01 to about 0.3 or a vinyl equivalent per kilogram of about 0.01 to about 0.1 or a combination of both.

18. The method of claim 15 , wherein said hydride functionalized polysiloxane has a viscosity of about 5 to about 11,000 cSt or cP at 25° C.

19. The method of claim 15 , wherein said hydride functionalized polysiloxane has a percent SiH content of about 3 to about 45% or a SiH content of about 0.5 to about 10 mmol/g or a combination of both.

20. The method of claim 15 , wherein said hydride functionalized polysiloxane is alkyl terminated.

21. The method of claim 15 , wherein said hydride functionalized polysiloxane comprises trimethylsiloxy terminated methylhydrosiloxane-dimethylsiloxane copolymers.

22. The method of claim 15 , wherein said reactive reinforcing component has a vinyl organopolysiloxane to functional hydride molar ratio of about 1:10 to about 1:100.

23. The method of claim 15 , wherein said reinforcing constituent is selected from the group consisting of optionally surface treated mica, zinc oxide, titanium dioxide, aluminum oxide, clay or silica.

24. The method of claim 15 , wherein the crosslinking component further comprises a catalyst that comprises about 0.005 to about 0.04% of the crosslinking component.

25. A method for treating eczema in a subject in need thereof, comprising:

applying to the skin of the subject a composition comprising

about 3,500 to about 20,000 cSt or cP at 25° C. vinyl-terminated dimethylpolysiloxane;

about 100,000 to about 175,000 cSt or cP at 25° C. vinyl-terminated dimethylpolysiloxane;

Alkyl-terminated silicon-hydride polysiloxane; and

Platinum-divinyltetramethyldisiloxane complex.

26. A method for treating eczema in a subject in need thereof, comprising:

applying to the skin of the subject a composition comprising:

about 10,000 cSt or cP at 25° C. vinyl-terminated dimethylpolysiloxane;

about 165,000 cSt or cP at 25° C. vinyl-terminated dimethylpolysiloxane;

Alkyl-terminated silicon-hydride polysiloxane; and

Platinum-divinyltetramethyldisiloxane complex,

thereby treating eczema in the subject.